All In Biotech

Drug Trial Radar · NCT06179875

An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

139

Actual

Start

Jan 31, 2024

Primary completion

Apr 25, 2025

Study completion Jun 23, 2025

Sponsor

Lead sponsor
Viridian Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with thyroid eye disease (TED). The primary objectives of this clinical trial are to provide open-label access to VRDN-001 for participants who were previously non-responders at 3 weeks post the fifth IV infusion (i.e., 15 weeks) in the VRDN-001-101 (THRIVE) and VRDN-001-301 (THRIVE-2) pivotal studies and assess the safety and efficacy of VRDN-001 in participants who were previously treated with VRDN-001 or placebo.

Conditions

  • Thyroid Eye Disease

Interventions

  • VeligrotugDrug

    Veligrotug 10 mg/kg (5 infusions of Veligrotug 10 mg/kg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by ExophthalmometerTime frame: Baseline to Week 15

Locations

45 sites in 8 countries. Site status is shown where the registry gives one.

  • Advancing Research International, LLC

    Los Angeles, California

  • USC Eye Institute

    Los Angeles, California

  • Advancing Research International, LLC

    Newport Beach, California

  • Stanford Byers Eye Institute

    Palo Alto, California

  • Cockerham Eye Consultants, PC

    San Diego, California

  • University of Miami Miller School of Medicine, Bascom Palmer Eye Institute

    Miami, Florida

  • Sarasota Retina Institute

    Sarasota, Florida

  • Vision Medical Research

    Oak Lawn, Illinois

  • Ophthalmic Consultants of Boston

    East Weymouth, Massachusetts

  • Kahana Oculoplastic & Orbital Surgery

    Livonia, Michigan

  • Ophthalmic Plastic, Reconstructive, Orbital and Cosmetic Surgery

    Las Vegas, Nevada

  • Rutgers New Jersey Medical School

    Newark, New Jersey

  • The Center for Eye and Facial Plastic Surgery

    Somerset, New Jersey

  • Hospital of the University of Pennsylvania Perleman Center

    Philadelphia, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • Neuro-Eye Clinical Trials

    Houston, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • University of Washington Medical Center

    Seattle, Washington

  • CHU Angers

    Angers, France

  • Centre Hospitalier Universitaire de Montpellier Hopital Lapeyronie

    Montpellier, Hérault, France

  • Centre Hospitalier Universitaire De Nantes G.R. Laenne

    Saint-Herblain, Loire-Atlantique, France

  • Charite - Universitatsmedizin Berlin KoR, Campus Virchow Klinikum, Klinik tor Augenheilkunde

    Berlin, Germany

  • Universitatsklinikum Carl Gustav Carus

    Dresden, Germany

  • Universitatsklinikum Essen AoR - Klinik fur Augenheilkunde

    Essen, Germany

  • University Medical Center Freiburg

    Freiburg im Breisgau, Germany

  • Universitatmedizin Gottingen

    Göttingen, Lower Saxony, Germany

  • Amsterdam UMC

    Amsterdam, Netherlands

  • Uniwersytecki Szpital Kliniczny w Bialymstoku

    Bialystok, Poland

  • Optimum Profesorskie Centrum Okulistyki

    Gdansk, Poland

  • Centrum Medyczne Pulawska

    Piaseczno, Poland

  • Centrum Medyczne Piasta

    Wałbrzych, Piasta, Poland

  • Hospital Arruzafa. Servicio de Oftalmologia

    Córdoba, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario Virgen de la Macarena

    Seville, Spain

  • Hospital Universitario Miguel Servel

    Zaragoza, Spain

  • Hacettepe Universitesi Tip Fakultesi

    Ankara, Turkey (Türkiye)

  • Gazi University Medical Faculty Hospital

    Ankara, Turkey (Türkiye)

  • Akdeniz University Medical Faculty Hospital

    Antalya, Turkey (Türkiye)

  • Marmara University Faculty of Medicine

    Istanbul, Turkey (Türkiye)

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.